Yarrow Bioscience (YARW) Change in Accured Expenses (2017 - 2026)

Yarrow Bioscience (YARW) has 10 years of Change in Accured Expenses data on file, last reported at -$1.2 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 53.41% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.9 million (down 290.08% YoY) and the FY2025 annual result came in at -$12.3 million, down 304.74% from the prior year.
• Change in Accured Expenses climbed to -$1.2 million in Q1 2026, from -$6.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.5 million in Q2 2024 to a low of -$9.6 million in Q1 2022.
• A 5-year average of -$885600.0 and a median of -$512000.0 in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 4782.93% — and 2024, when it surged 1072.73%.
• Tracing YARW's Change in Accured Expenses over 5 years: stood at $2.5 million in 2022, then slumped by 60.61% to $993000.0 in 2023, then soared by 121.55% to $2.2 million in 2024, then plunged by 391.18% to -$6.4 million in 2025, then jumped by 81.89% to -$1.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.2 million (Q1 2026), -$6.4 million (Q2 2025), and -$2.5 million (Q1 2025), per Business Quant data.